Ticagrelor-Based Dual Antiplatelet Therapy Duration in CABG

This randomized controlled trial aims to evaluate the impact of different durations of Ticagrelor-based dual antiplatelet therapy (DAPT) on saphenous vein graft (SVG) patency in patients undergoing coronary artery bypass grafting (CABG). A total of 300 patients will be randomly assigned to receive Ticagrelor (90 mg BID) + Aspirin (100 mg QD) for 3 months, 6 months, or 12 months, followed by aspirin monotherapy.The primary outcome is 1-year graft patency, assessed via coronary CT angiography. Secondary outcomes include bleeding events (BARC classification), major adverse cardiovascular and cerebrovascular events (MACCE), and all-cause mortality. The study aims to determine the optimal DAPT duration to balance graft patency benefits and bleeding risks, ultimately guiding postoperative antiplatelet strategies for CABG patients.

NCT Number	NCT06981390
Lead Sponsor	Kexiang Liu, MD
Conditions	Coronary Artery Disease, Coronary Artery Bypass Grafting, Saphenous Vein, Dual Antiplatelet Therapy
Enrollment	300 participants
Start Date	2026-05-01
Primary Completion	2027-02-20 (estimated)
Study Completion	2027-03-20 (estimated)
Updated on ClinicalTrials.gov	2026-04-24